- Home
- LOBO vs RLMD Comparison
LOBO vs RLMD Comparison
Compare LOBO & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOBO
- RLMD
- Stock Information
- Founded
- LOBO 2014
- RLMD 2004
- Country
- LOBO China
- RLMD United States
- Employees
- LOBO N/A
- RLMD N/A
- Industry
- LOBO
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- LOBO
- RLMD Health Care
- Exchange
- LOBO NYSE
- RLMD Nasdaq
- Market Cap
- LOBO 13.6M
- RLMD 11.5M
- IPO Year
- LOBO 2024
- RLMD N/A
- Fundamental
- Price
- LOBO $0.80
- RLMD $0.69
- Analyst Decision
- LOBO
- RLMD Hold
- Analyst Count
- LOBO 0
- RLMD 4
- Target Price
- LOBO N/A
- RLMD $4.25
- AVG Volume (30 Days)
- LOBO 52.0K
- RLMD 2.1M
- Earning Date
- LOBO 04-29-2025
- RLMD 05-07-2025
- Dividend Yield
- LOBO N/A
- RLMD N/A
- EPS Growth
- LOBO N/A
- RLMD N/A
- EPS
- LOBO 0.00
- RLMD N/A
- Revenue
- LOBO $19,469,766.00
- RLMD N/A
- Revenue This Year
- LOBO $72.16
- RLMD N/A
- Revenue Next Year
- LOBO $41.04
- RLMD N/A
- P/E Ratio
- LOBO $741.89
- RLMD N/A
- Revenue Growth
- LOBO N/A
- RLMD N/A
- 52 Week Low
- LOBO $0.46
- RLMD $0.24
- 52 Week High
- LOBO $3.52
- RLMD $4.47
- Technical
- Relative Strength Index (RSI)
- LOBO N/A
- RLMD 87.66
- Support Level
- LOBO N/A
- RLMD $0.27
- Resistance Level
- LOBO N/A
- RLMD $0.33
- Average True Range (ATR)
- LOBO 0.00
- RLMD 0.06
- MACD
- LOBO 0.00
- RLMD 0.03
- Stochastic Oscillator
- LOBO 0.00
- RLMD 97.81
About LOBO LOBO EV TECHNOLOGIES LTD
Lobo EV Technologies Ltd is an electric vehicle manufacturer and seller company. It designs, develops, manufactures, and sells e-bicycles, e-mopeds, e-tricycles, and electric off-highway four-wheeled shuttles such as golf carts and mobility scooters for the elderly and disabled persons, also provides automobile information and entertainment software development and design services to customers. The company operates in two operating segments: Electric vehicles and accessories sales which generates key revenue, and software royalties and development and design services. It generates all of its revenue within the People's Republic of China.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.